Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Shrink Nanotechnologies, Inc. (INKN.OB) Reveals Image of their First Product Offering

Shrink Nanotechnologies, Inc. revealed an image of their first product offering – the StemDisc450™. This product is a high-yield, low cost, patent-pending cell culturing biomedical research tool. The Company expects to begin offering this product for sale in the latter part of 2010.

The design of StemDisc is to improve embryoid body (NYSE:EB) formation of stem cells at a higher rate and efficiency over current EB formation methods. The platform can be used to grow and differentiate human and animal single cells, human embryonic stem cells (HESCs) and induced pluri-potent stem cells (IPSCs).

Versions of StemDisc’s unique honeycomb-like well will be offered in different diameter and depth. This is depending on the type of cell and application. Each round bottom “microwell” is capable of making 800 to 1,000 EBs. This increases the flexibility of use for researchers to achieve optimum EB formation with high reliability compared to legacy methods.

A unique feature of the StemDisc product line is the optical transparency of the surface that the cells rest in. The StemDisc polymer offers premier transparency. This provides cell biologists with the ability to see more of what they are doing as they complete their research. StemDisc’s five micron walls between microwells virtually assure a clean transfer of the biological material into a well – in a few easy steps. This helps to further lower costs and speed up the time to publish results of potentially life-saving studies.

Mr. Mark L. Baum, CEO of Shrink Nanotechnologies, Inc., said, “Tissue engineering and cell culturing are high growth areas of the biotechnology field. This trend is being fueled as the idea of ‘personalized medicine’ – or ‘therapeutics and treatments made for you’ – becomes a reality. And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson’s and Alzheimer’s disease, and many more. StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools.”

“We have started field testing of our first StemDisc450 prototypes, and we anticipate being able to show time lapse videos of this product performing, and actually developing HESCs (human embryonic stem cells) and IPSCs (induced pluripotent stem cells),” added Baum. “Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc™ products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States.”

Shrink Nanotechnologies, Inc. is an innovative nanotechnology company with headquarters in Carlsbad, California. The Company is developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses.

The Company is a one-of-a-kind FIGA™ organization. They focus on taking advantage of contributions from experts in finance, industry, government and academia. Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. Their unique NanoShrink™ material is a pre-stressed polymer that is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries.

For more information visit: shrinknano.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net


Disclosure: no poaitions